IP Library Granted Patent US 9,271,493
Granted Patent B2
US 9,271,493 · App. 13/921,916 · Granted Mar 1, 2016

Methods for microbial biofilm destruction

Inventors: Lynette Cegelski (Stanford, CA); Ji Youn Lim (Stanford, CA)
Assignee: The Board of Trustees of the Leland Stanford Junior University
A01N35/02A61K31/12A61K45/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,271,493
App. No.
13/921,916
Granted
Mar 1, 2016
Kind
B2
Abstract

Compositions and methods for the dissolution of a microbial biofilm are provided, where the method comprises contacting a microbiofilm with an effective dose of a curcumin derivative as a biofilm inhibitor. In some embodiments the curcumin derivative is dimethoxycurcumin. In some embodiments the biofilm comprises E. coli , e.g. including uropathogenic E. coli . The biofilm can be present in vitro or in vivo. The biofilm inhibitor may be administered alone, or in combination with bacteriocidal agents.

Claims (11)

1. A method of inhibiting microbial biofilm maintenance or formation, the method consisting of:

contacting microbes involved in said biofilm formation or maintenance with an effective dose of dimethoxycurcumin (1, 7-bis(3, 4-dimethoxyphenyl)-1, 6-heptadiene-3, 5-dione), wherein the effective dose provides for a concentration at the biofilm site of from about 0.01 μM to about 10 mM.

2. The method of claim 1 , wherein said biofilm is present in vitro.

3. The method of claim 1 , wherein said biofilm is present in vivo.

4. The method of claim 1 , wherein the biofilm comprises E. coli.

5. The method of claim 1 , wherein the biofilm comprises uropathogenic or enterohemorrhagic microorganisms.

6. The method of claim 4 , wherein the biofilm comprises uropathogenic E. coli.

7. The method of claim 3 , wherein an effective daily dose ranges from about 0.5 mg to about 500 g.

8. The method according to claim 1 , further comprising contacting microbes involved in said biofilm formation or maintenance with an effective dose of a bactericidal agent in combination with said dimethoxycurcumin.

9. The method of claim 1 , wherein the dimethoxycurcumin inhibits biofilm extracellularly.

10. The method of claim 3 , wherein the biofilm is present in a human individual.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 3, 2013
From: CEGELSKI, LYNETTE; LIM, JI YOUN
To: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
Reel/Frame 031129/0544 →
CONFIRMATORY LICENSE Recorded Jul 3, 2013
From: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 030746/0801 →
Continuity (2)
Provisional Application 61661626 · Jun 19, 2012
Related Publication 20130338233A1 · Dec 19, 2013